PAMP
CSTL icon

Polar Asset Management Partners’s Castle Biosciences CSTL Stock Holding History

Polar Asset Management Partners’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-60,800
Closed -$1.35M – 729
2024
Q1 		$1.35M Buy
60,800
+7,600
+14% +$165K 0.02% 408
2023
Q4 		$1.15M Buy
+53,200
New +$936K 0.02% 413
2023
Q1 		– Sell
-107,100
Closed -$2.52M – 1080
2022
Q4 		$2.52M Buy
+107,100
New +$2.48M 0.03% 591
2021
Q4 		– Sell
-95,504
Closed -$6.35M – 1347
2021
Q3 		$6.35M Sell
95,504
-18,400
-16% -$1.29M 0.06% 342
2021
Q2 		$8.35M Buy
+113,904
New +$7.52M 0.09% 261

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Polar Asset Management Partners's CSTL Position: Q2 2024 in Review

Polar Asset Management Partners sold out of Castle Biosciences (CSTL) in Q2 2024, closing a stake of 60,800 shares — an estimated $1.35M sold.

Polar Asset Management Partners first reported a position in CSTL in Q2 2021 and held it in 5 quarters. The position peaked at $8.35M in Q2 2021. 159 funds tracked by Wall St. Rank hold CSTL as of Q2 2024.

  • Polar Asset Management Partners reported no remaining Castle Biosciences position as of Q2 2024 after selling out during the quarter.
  • Polar Asset Management Partners sold 60,800 Castle Biosciences shares in Q2 2024, an estimated $1.35M.
  • Polar Asset Management Partners first reported a position in Castle Biosciences in Q2 2021 and held it in 5 quarters.
  • Polar Asset Management Partners's Castle Biosciences position peaked at $8.35M in Q2 2021.
  • 159 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2024.

Based on Polar Asset Management Partners's 13F filing for Q2 2024, filed 14 Aug 2024.